Background: Rheumatologic diseases are the most prevalent diseases orldwide. About one-third of physical disabilities in elderly are due to heumatologic etiological disorders as a primary cause. They are one of the main causes of disability and morbidity all over the world with great impact on the quality of life. Aim: The aim of this study was to examine the profiles of rheumatic diseases of the admitted patients to Assiut University hospital and to compare them with that of non-Arabic countries. Material and Methods: Descriptive study of 939 patients with heumatologic diseases during the period study (from January 2011 and April 2014). Diagnosis of the patients was done after fulfilling ACR/EULAR diagnostic criteria of each disease and required investigations were also done for verifying related diagnosis. Results: The total number of patients was 939, with (79.1%) female predominance. Age ranged from 7-79 years with a mean ± SD 38 ±15.32. Rheumatoid Arthritis (RA) was presented in 36.8%, Systemic Lupus Erythematosus (SLE) in 14.3%, Crystal Arthropathy in 11.7%, Seronegative Spondyloarthropathy (SpA) in 10.3%, Behçet disease (BD) in 8.3%, Juvenile Idiopathic Arthritis (JIA) in 6.4%, Systemic Sclerosis (SSc) in 5.8%, Overlap Syndrome in 2.9%, Antiphospholipid Syndrome (APS) in 0.3% and Adult onset Still`s Disease in 0.3%. Conclusion: Rheumatoid arthritis was the most common rheumatologic disease followed by Systemic Lupus Erythematosus in admitted patients of the Rheumatology, Rehabilitation, and Physical Medicine Department, Assiut University hospital.

NULL

NULL

NULL

We identified that type 2 immunity stimulation has been associated with the pathogenesis of Systemic lupus Erythematous (SLE), so we studied serum level of IL 25 and its relation to SLE activity, clinical and laboratory characteristics. Methods: Serum from 90 patients who met the American College of Rheumatology (ACR) criteria for SLE and 40 healthy controls was tested for IL 25 level by Enzyme Linked Immunosorbent Assay (ELSIA). Clinical and laboratory characteristics and disease activity using SLE Disease Activity Index (SLEDAI) were also assessed. Results: IL 25 serum level was signi?cantly higher among SLE patients than healthy controls. It has statistically signi?cant correlation with disease activity. Conclusion: Our data indicates that IL 25 level is elevated in SLE patients in comparison to healthy controls and is correlated to high disease activity, potentially being a biomarker predictive for disease activity in SLE.

We identified that type 2 immunity stimulation has been associated with the pathogenesis of Systemic lupus Erythematous (SLE), so we studied serum level of IL 25 and its relation to SLE activity, clinical and laboratory characteristics. Methods: Serum from 90 patients who met the American College of Rheumatology (ACR) criteria for SLE and 40 healthy controls was tested for IL 25 level by Enzyme Linked Immunosorbent Assay (ELSIA). Clinical and laboratory characteristics and disease activity using SLE Disease Activity Index (SLEDAI) were also assessed. Results: IL 25 serum level was signi?cantly higher among SLE patients than healthy controls. It has statistically signi?cant correlation with disease activity. Conclusion: Our data indicates that IL 25 level is elevated in SLE patients in comparison to healthy controls and is correlated to high disease activity, potentially being a biomarker predictive for disease activity in SLE.

A correlation was detected between the chemokine CXC ligand 13(CXCL13) and lupus nephritis, but there is no data recorded in literature about a relationship with other disease manifestations in systemic lupus erythematosus (SLE). Therefore, we sought to investigate the relationship between CXCL13 and overall disease activity and other disease manifestations in SLE.

A correlation was detected between the chemokine CXC ligand 13(CXCL13) and lupus nephritis, but there is no data recorded in literature about a relationship with other disease manifestations in systemic lupus erythematosus (SLE). Therefore, we sought to investigate the relationship between CXCL13 and overall disease activity and other disease manifestations in SLE.

A correlation was detected between the chemokine CXC ligand 13(CXCL13) and lupus nephritis, but there is no data recorded in literature about a relationship with other disease manifestations in systemic lupus erythematosus (SLE). Therefore, we sought to investigate the relationship between CXCL13 and overall disease activity and other disease manifestations in SLE.

A correlation was detected between the chemokine CXC ligand 13(CXCL13) and lupus nephritis, but there is no data recorded in literature about a relationship with other disease manifestations in systemic lupus erythematosus (SLE). Therefore, we sought to investigate the relationship between CXCL13 and overall disease activity and other disease manifestations in SLE.